Offit Kurman welcomes Christopher Halliday to the firm’s Intellectual Property Practice Group in its Philadelphia, PA, office. With nearly three decades of experience in patent prosecution, IP transactions, and corporate due diligence, Chris brings deep insight to companies across the life sciences sector, including biotech firms, MedTech companies, and global pharmaceutical organizations.
Chris focuses his practice on biologics, pharmaceuticals, and medical devices, where he excels at designing IP strategies that protect innovation, align with business goals, and enhance market exclusivity. His understanding of the life sciences ecosystem enables him to help clients anticipate industry-specific challenges and craft solutions that support their long-term success.
In addition to his patent prosecution work, Chris frequently advises on IP-driven transactions, such as mergers, acquisitions, and licensing agreements, ensuring that clients’ intellectual assets are protected and positioned for commercial growth. His role in corporate due diligence is pivotal, assisting companies and investors as they assess potential risks and opportunities in high-stakes acquisitions and investments. R&D-focused organizations and major venture capital firms rely on Chris for his ability to translate complex scientific concepts into clear, actionable legal strategies.
Chris’ arrival further strengthens Offit Kurman’s position as a trusted partner for life sciences innovators, providing clients with comprehensive IP solutions that safeguard their intellectual property and drive growth.
